| [1] |
Kröger N,Giorgino T,Scott BL, et al.Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis[J]. Blood, 2015, 125(21): 3347-3350.
|
| [2] |
Mohyuddin GR,Yacoub A. Primary myelofibrosis presenting as extramedullary hematopoiesis in a transplanted liver rraft：case report and review of the literature[J]. Case Rep Hematol, 2016: 9515404.
|
| [3] |
Maia RC,Bonamino MH,Robaina MC, et al.An unusual long-term outcome of a child with primary myelofibrosis harboring a JAK2 mutation[J]. Blood Cells Mol Dis, 2015, 55(4): 347-350.
|
| [4] |
Pistevou-Gombaki K,Zygogianni A,Kantzou I, et al.Splenic irradi ation as palliative treatment for symptomatic splenomegaly due to secondary myelofibrosis：a multi-institutional experience[J]. J BUON, 2015, 20(4): 1132-1136.
|
| [5] |
Webb M,Shibolet O,Halpern Z, et al.Assessment of liver and spleen stiffness in patients with myelofibrosis using fibroscan and shear wave elastography[J]. Ultrasound Q, 2015, 31(3): 166-169.
|
| [6] |
Ayl1 M,özcan M,Cengiz Seval G. Ruxolitinib treatment in a patient with primary myelofibrosis resistant to conventional therapies and splenectomy：a case report[J]. Turk J Haematol, 2015, 32(2): 180-183.
|
| [7] |
El Fakih R,Popat U. Janus Kinase Inhibitors and Stem Cell Trans plantation in Myelofibrosis[J]. Clin Lymphoma Myeloma Leuk, 2015(15): S34-S42.
|
| [8] |
Duenas-Perez AB,Mead AJ.Clinical potential of pacritinib in the treatment of myelofibrosis[J]. Ther Adv Hematol, 2015, 6(4): 186-201.
|
| [9] |
Wassie E,Finke C,Gangat N, et al.A compendium of cytogenetic abnormalities in myelofibrosis：molecular and phenotypic correlates in 826 patients[J]. Br J Haematol, 2015, 169(1): 71-76.
|
| [10] |
Kröger N. Current challenges in stem cell transplantation in myelofi brosis[J]. Curr Hematol Malig Rep, 2015, 10(4): 344-350.
|
| [11] |
Breccia M,Molica M,Colafigli G, et al.Improvement of bone marrow fibrosis with ruxolitinib：will this finding change our perception of the drug？[J]. Expert Rev Hematol, 2015, 8(4): 387-389.
|
| [12] |
Markiewicz M,Dzierzak Mietla M,Wieczorkiewicz A, et al.Safety and outcome of allogeneic stem cell transplantation in myelofibrosis[J]. Eur J Haematol, 2016, 96(3): 222-228.
|
| [13] |
Hasselbalch HC.Perspectives on the increased risk of second cancer in patients with essential thrombocythemia polycythemia vera and myelofibrosis[J]. Eur J Haematology, 2015, 94(2): 96-98.
|
| [14] |
Derlin T,Alchalby H,Bannas P, et al.Assessment of bone marrow inflammation in patients with myelofibrosis：an 18F-fluorodeoxyglucose PET/CT study[J]. Eur J Nucl Med Mol Imaging, 2015, 42(5): 696-705.
|
| [15] |
Lane SW,Mullally A. Hit the spleen, JAK！[J]. Blood, 2014, 124(19): 2898-2900.
|
| [16] |
Jung CW,Shih LY,Xiao Z, et al.Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis[J]. Leuk Lymphoma, 2015, 56(7): 2067-2074.
|
| [17] |
Santos FP,Verstovsek S. Efficacy of ruxolitinib for myelofibrosis[J]. Expert Opin Pharmacother, 2014, 15(10): 1465-1473.
|
| [18] |
Gabali AM,Jazaerly T,Chang CC, et al.Simultaneous hepatosplenic T-cell lymphoma and myelofibrosis[J]. Avicenna J Med, 2014, 4(2): 34-36.
|
| [19] |
Shimoda K,Takenaka K,Kitanaka A, et al.Clinical aspects of primary myelofibrosis in Japan[J]. Rinsho Ketsueki, 2014, 55(3): 289-294.
|
| [20] |
Mughal TI,Vaddi K,Sarlis NJ, et al.Myelofibrosis-associated com plications：pathogenesis, clinical manifestations, and effects on outcomes[J]. Int J Gen Med, 2014(7): 89-101.
|